---
title: "Addex says preclinical study shows mGlu7 inhibitor ADX71743 boosts wakefulness in rats"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292013939.md"
description: "Addex Therapeutics reported preclinical data showing its mGlu7 inhibitor, ADX71743, significantly increased wakefulness in rats by reducing REM and non-REM sleep. The study also noted changes in stress-linked neurotransmitters, suggesting mGlu7 modulation as a potential target for central nervous system disorders."
datetime: "2026-07-08T05:00:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292013939.md)
  - [en](https://longbridge.com/en/news/292013939.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292013939.md)
generator: "portal-rs"
---

# Addex says preclinical study shows mGlu7 inhibitor ADX71743 boosts wakefulness in rats

-   Addex flagged new preclinical data showing its mGlu7 inhibitor ADX71743 significantly shifted sleep-wake patterns in rat studies. \* ADX71743 increased wakefulness, cutting REM sleep and non-REM sleep. \* Study also showed changes in stress-linked neurotransmitters, supporting mGlu7 modulation as a potential target in CNS disorders. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Addex Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607080100PRIMZONEFULLFEED1001211715) on July 08, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [ADXN.US](https://longbridge.com/en/quote/ADXN.US.md)

## Related News & Research

- [AC Immune reports positive interim Phase 1 data for NLRP3 inhibitor ACI-19764](https://longbridge.com/en/news/296478492.md)
- [Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) Enters LOI for Exclusive Option on LAG-3 Inhibitor Program](https://longbridge.com/en/news/296513179.md)
- [Eikon CEO Perlmutter joins Cantor Fitzgerald KOL webcast on PARP inhibitors in oncology](https://longbridge.com/en/news/296265619.md)
- [Ocular Therapeutix Earns Buy Rating as Axpaxli Differentiation and LUGANO TKI Data Bolster Confidence in Lead Asset](https://longbridge.com/en/news/296129081.md)
- [Tesla (TSLA) recalls over 2 million cars in China to add driver monitoring](https://longbridge.com/en/news/296628945.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**